Application

Research CategoryApoptosis & Cancer

Research Sub CategoryApoptosis - Additional

This Anti-CLEC2A Antibody, clone 8D2.1 is validated for use in Western Blotting for the detection of CLEC2A.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

C-type lectin domain family 2 member A (CLEC2A) is also called proliferation-induced lymphocyte-associated receptor (PILAR) and Keratinocyte-associated C-type lectin (KACL). CLEC2A is involved in modulating T-cell expansion. It is a 32 kDa single-pass type II membrane protein that belongs to the CTL/CTLD superfamily. CLEC2A is mainly expressed in skin and highly expressed in CD8(+), B lymphocytes and naive CD4(+) T cells. Modulation of CLEC2A signaling may be important for treatment of autoimmune diseases and cancer. CLEC2A is associated with expansion of TCR-stimulated T-cells, modulates the capacity of T-cells to home to lymph nodes through SELL, and facilitates immune recognition of keratinocytes by stimulating natural killer cell mediated cytotoxicity.

Immunogen

Epitope: Extracellular domain

KLH-conjugated linear peptide corresponding to the extracellular domain of human CLEC2A.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Protein G Purified

Format: Purified

Quality

Evaluated by Western Blotting in Raji cell lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected CLEC2A in 200 µg of Raji cell lysate.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~18 kDa observed